Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections. Current progress and future perspectives in drug discovery against EV-Bs are briefly discussed and existing gaps are spotlighted.

Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances / Tammaro, Chiara; Guida, Michela; Appetecchia, Federico; Biava, Mariangela; Consalvi, Sara; Poce, Giovanna. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 16:2(2023), p. 203. [10.3390/ph16020203]

Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances

Chiara Tammaro
Primo
;
Michela Guida
Secondo
;
Federico Appetecchia;Mariangela Biava;Sara Consalvi
Penultimo
;
Giovanna Poce
Ultimo
2023

Abstract

Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections. Current progress and future perspectives in drug discovery against EV-Bs are briefly discussed and existing gaps are spotlighted.
2023
Enterovirus-B; Coxsackievirus; Enterovirus-B inhibitors; drug discovery; antivirals
01 Pubblicazione su rivista::01a Articolo in rivista
Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances / Tammaro, Chiara; Guida, Michela; Appetecchia, Federico; Biava, Mariangela; Consalvi, Sara; Poce, Giovanna. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 16:2(2023), p. 203. [10.3390/ph16020203]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1668339
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact